Benzinga · Sep 8, 2026
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
OS
NYSE · OSTX
OS Therapies Incorporated
Healthcare · Biotechnology
$1.78
Up+$0.00 (+0.28%)
Updated Sep 16, 2026, 1:40 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 71.66M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $1.15 – $2.32
- Volume
- 1.05M
- Avg. volume
- 342.06K
Price performance
OSTX price history
1M range · 20 trading sessions · Daily adjusted prices
OSTX closed at $1.78 after 20 trading sessions, up 23.61% for the selected period.
- Last close
- $1.78
- Period change
- +23.61%
- Period low
- $1.44
- Period high
- $1.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.78 | $1.81 | $1.71 | $1.78 | 1.05M |
| Sep 14, 2026 | $1.65 | $1.79 | $1.62 | $1.70 | 993.72K |
| Sep 11, 2026 | $1.81 | $1.8399 | $1.66 | $1.68 | 825.87K |
| Sep 10, 2026 | $1.87 | $1.92 | $1.81 | $1.82 | 547.91K |
| Sep 9, 2026 | $1.83 | $1.92 | $1.80 | $1.86 | 393.18K |
| Sep 8, 2026 | $1.96 | $2.015 | $1.7504 | $1.83 | 1.77M |
| Sep 4, 2026 | $1.84 | $1.96 | $1.84 | $1.88 | 982.58K |
| Sep 3, 2026 | $1.72 | $1.84 | $1.72 | $1.82 | 894.28K |
| Sep 2, 2026 | $1.68 | $1.72 | $1.61 | $1.71 | 530.47K |
| Sep 1, 2026 | $1.68 | $1.705 | $1.63 | $1.66 | 400.62K |
| Aug 31, 2026 | $1.62 | $1.6901 | $1.62 | $1.69 | 234.96K |
| Aug 28, 2026 | $1.69 | $1.69 | $1.60 | $1.64 | 294.98K |
| Aug 27, 2026 | $1.65 | $1.72 | $1.641 | $1.68 | 518.15K |
| Aug 26, 2026 | $1.65 | $1.65 | $1.60 | $1.65 | 351.46K |
| Aug 25, 2026 | $1.53 | $1.65 | $1.53 | $1.65 | 351.23K |
| Aug 24, 2026 | $1.50 | $1.55 | $1.4602 | $1.55 | 438.88K |
| Aug 21, 2026 | $1.56 | $1.635 | $1.56 | $1.59 | 386.42K |
| Aug 20, 2026 | $1.50 | $1.58 | $1.45 | $1.58 | 369.64K |
| Aug 19, 2026 | $1.46 | $1.47 | $1.40 | $1.46 | 283.64K |
| Aug 18, 2026 | $1.48 | $1.51 | $1.43 | $1.44 | 231.51K |
Latest OSTX news
The latest Smart Investors Daily articles mentioning OSTX.
Stock researchCompany · Overview
OSTX research
Overview
Company profile and research snapshot.
Company profile
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.01
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | Roth Capital | Buy | — |
| May 19, 2026 | Lake Street | Buy | — |
| Apr 30, 2026 | D. Boral Capital | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 27, 2026 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial monitoring visits scheduled for September 2026 and early October 2026Company receives $3.15 million in VAT refunds into OS Therapies UK, Ltd. subsidiary, with an additional $7.2 million in refundable VAT and R&D Tax Credits pendingNew York, New York and Rockville,...
Benzinga · Sep 8, 2026
OS Therapies Announces Statistically Significant Benefit For OST-HER2-Treated Patients In An Interim 3-Year Overall Survival Data Analysis
Overall survival data when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the Company's Phase 2b trial for the prevention or delay of
Yahoo · Sep 2, 2026
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJapan Interim 3-year overall survival data, U.S. FDA Type C Statistical Methods meeting and U.K. MHRA Statistical Methods Scientific Advice Meeting expected in September 2026RMAT and Rolling Review decisions expected to follow U.S. FDA meetingFinal 3-year overall survival data,...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
